José A. Mira-Escarti-rekin lankidetzan egindako argitalpenak (5)

2007

  1. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235

  2. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529

2006

  1. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C

    Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846

  2. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 58, Núm. 1, pp. 140-146

  3. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

    Gut, Vol. 55, Núm. 3, pp. 409-414